Godavari Drugs Limited (530317) Fair Value & Analysis
Other · IN · Market cap ₹270M
Fair value as of: Jul 4, 2026
From 15 valuation models · updated today
Share price +1.0% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹70.24 – ₹130.15 · fair‑value band ₹66.02 – ₹99.31 · the ₹123.95 price screens above the ₹76.39 fair value. As of Jul 4, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Godavari Drugs Limited (530317) currently trades at ₹123.95, while our model-based Fair Value estimate is ₹76.39 — implying the stock looks roughly 38.4% overvalued today. We read business quality at 31/100 (below-average quality), in the Other sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Godavari Drugs Limited generated revenue of ₹993M at a net margin of 2.4%. Revenue grew 15.0% year over year. Net debt stands at ₹618M. The stock trades on a trailing P/E of 11.0. Fundamentals as of Jul 4, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 4, 2026. TTM = trailing twelve months.
About the company
Godavari Drugs Limited manufactures and supplies active pharmaceutical ingredients (APIs), drug intermediaries, and fine chemicals in India. It offers APIs, including ciprofloxacin HCl, ciprofloxacin lactate, ciprofloxacin betaine, mefenamic acid, enrofloxacin, and elthambutoal HCI; and intermediaries, such as A D lactone for spironolactone and 6 mercaptopurine for azathioprine. The company also provides loan license and contract manufacturing services. It serves the life science industry. The company was incorporated in 1987 and is based in Secunderabad, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Godavari Drugs Limited reported revenue of ₹1.1B in FY2026 versus ₹1.6B in FY2022, a compound −10.0%/yr. Reported net income was ₹40.9M in FY2026, compounding −6.0%/yr from FY2022.
Is 530317 fairly valued? → Check now
Similar stocks
6 more Other stocks, each showing price versus our Fair Value estimate (as of Jul 4, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| There MOH | €521.90 | €269.92 | -48% |
| Sony Corporation SON1 | €17.58 | €39.38 | +124% |
| Federal Home Loan Mortgage Corporation FREJO | $16.84 | $64.93 | +286% |
| 533278 533278 | ₹438.60 | ₹720.31 | +64% |
| Nestl?? India Limited 500790 | ₹1,459 | ₹279.60 | -81% |
| 540376 540376 | ₹3,993 | ₹1,806 | -55% |
Explore undervalued stocks
Frequently asked questions
Is Godavari Drugs Limited (530317) undervalued?
What is the fair value of 530317?
What is the quality score of 530317?
What is the revenue of Godavari Drugs Limited (530317)?
What is the net profit margin of 530317?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.